Amvuttra Approved for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

The FDA has approved Amvuttra for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Related Keywords

,Drug Administration ,Alnylam Pharmaceuticals Inc ,Neuropathy Impairment Score ,Norfolk Quality ,Life Questionnaire Diabetic Neuropathy ,Accessed June ,